The decision does not reflect new concerns about the clinical efficacy or safety data from the phase 3 CARES-310 trial.
News|Videos|May 27, 2024 (Updated: September 13, 2024)
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Patients With Poor Prognosis Hepatocellular Carcinoma
Author(s)William P. Harris, MD
William Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma
3
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
4
Adjuvant Penpulimab Improves DFS in Very High-Risk Clear Cell RCC
5